Research · Sep 3, 2026
[IQV] IQVIA Thesis 2026: Clinical Trial Backlog Anchors Multi-Year Revenue Visibility
IQVIA Holdings Inc. FY2025 revenue ~$15.5-16B (+3-5%) with adj. EPS ~$11.20-11.50 reflecting continued clinical trial backlog conversion + selected GLP-1/biotech funding environment selected mixed + selected pricing + selected technology + analytics growth + selected operational discipline. Largest global clinical research organization (CRO) + healthcare data analytics company; formed via October 2016 merger of IMS Health (healthcare data analytics) + Quintiles (clinical research organization) for $17.6B all-stock combined market cap. 3 segments: Research & Development Solutions ~56% ($9B — clinical trial services full service contract research organization protocol design + clinical operations + monitoring + data management + biostatistics + regulatory + selected; ~$30B+ contracted backlog providing 2-3 year revenue visibility) + Technology & Analytics Solutions ~35% ($5.5B — pharma data analytics + IQVIA OneKey ~2M+ healthcare professional database + selected commercial intelligence + selected real-world evidence; higher operating margin 25-29%) + Contract Sales & Medical Solutions ~9% ($1.5B — pharma sales force outsourcing + medical affairs). CEO Ari Bousbib since 2010 (long-tenured CEO from IMS Health pre-IQVIA merger era; ex-IMS Health CEO 2010-2016 + ex-United Technologies Group President; ~30+ year industrial executive career). Bousbib led 2016 IMS + Quintiles merger; selected operational excellence + selected M&A integration. Capital return: no dividend + buybacks $1-1.5B (~modest share count reduction; share count 188M FY2022 → 177M FY2025E ~6% reduction over 3 years); net debt $13-14B; Baa3/BBB- investment grade. FY2026 thesis: backlog conversion + TAS growth + biotech cycle navigation + capital return. Risks: pharma R&D cycle, GLP-1/biotech funding environment, AI disruption to traditional CRO model.